Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about Phase 2 Trial
Recent news which mentions Phase 2 Trial
< Previous
1
2
3
4
5
6
7
8
9
Next >
ASLAN Pharma Kickstarts Mid-Stage Atopic Dermatitis Trial, Data Expected In 2023
January 21, 2022
Tickers
ASLN
Tags
Phase 2 Trial
atopic dermatitis
Trading Ideas
From
Benzinga
Opiant Pharma Starts Dosing In OPNT002 Mid-Stage Study For Alcohol Use Disorder
January 21, 2022
Tickers
OPNT
Tags
General
News
Health Care
From
Benzinga
FDA Clears Turning Point's IND For Elzovantinib + Aumolertinib Combo Regime In Lung Cancer Setting
January 20, 2022
Tickers
EQRX
TPTX
Tags
Phase 1 Trial
News
General
From
Benzinga
FDA Gives Green Signal To Compass Therapeutics' Mid-Stage Biliary Tract Cancer Trial In US
January 20, 2022
Tickers
CMPX
Tags
CMPX
Market News
Health Care
From
Benzinga
FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors
January 20, 2022
Tickers
NUVB
Tags
Small Cap
Health Care
Market News
From
Benzinga
KemPharm To Develop KP1077 As Lead SDX Candidate For Chronic Sleep Disorder
January 20, 2022
Tickers
KMPH
Tags
Earnings
Benzinga
Biotech
From
Benzinga
Leap Therapeutics Says DKN-01 Combo Regime Show Compelling Efficacy In Gastric Cancer Patients
January 19, 2022
Tickers
BGNE
LPTX
Tags
Movers
Health Care
Market News
From
Benzinga
Cardiff Oncology Slumps On New Data From Lead Program In Metastatic Colorectal Cancer
January 19, 2022
Tickers
CRDF
Tags
General
News
Phase 1 Trial
From
Benzinga
RedHill Biopharma's Oral COVID-19 Treatment Improves Median Time To Viral RNA Clearance
January 13, 2022
Tickers
RDHL
Tags
Briefs
Phase 2 Trial
News
From
Benzinga
Vaxcyte Raises $100M Via Equity To Fund Development Of Lead Pneumococcal Vaccine Candidate
January 13, 2022
Tickers
PCVX
Tags
Market News
Health Care
Movers
From
Benzinga
Ocugen Reveals Data From Bharat Biotech Partnered Covaxin Booster Dose
January 10, 2022
Tickers
OCGN
Tags
Benzinga
why it's moving
Biotech
From
Benzinga
Exclusive: Longeveron Kickstarts Its Mid-Stage Alzheimer's Disease Trial
January 05, 2022
Tickers
LGVN
Tags
Benzinga
Exclusives
LGVN
From
Benzinga
Annexon's Interim Mid-Stage Results On Huntington's Disease Candidate Fails To Cheer
January 05, 2022
Tickers
ANNX
Tags
Small Cap
Market News
Movers
From
Benzinga
Mereo BioPharma's Alvelestat Shows Improvement In COVID-19 Severity
December 22, 2021
Tickers
MREO
Tags
COVID/19 Coronavirus
Market News
Health Care
From
Benzinga
PhaseBio Pulls Plug On Mid-Stage Hypertension Asset
December 21, 2021
Tickers
PHAS
Tags
Movers
Health Care
Market News
From
Benzinga
Adverum Outlines Development Plan For ADVM-022 Gene Therapy In Wet AMD
December 21, 2021
Tickers
ADVM
Tags
Phase 2 Trial
Briefs
ADVM
From
Benzinga
CytomX Posts Interim Data From Phase 2 Trial Of CD71-Targeting Cancer Candidate
December 21, 2021
Tickers
ABBV
CTMX
Tags
Trading Ideas
Briefs
Non/Small Cell Lung Cancer
From
Benzinga
Can-Fite Shares Rally As Namodenoson Clears All Cancer Lesions In Liver Cancer Patient
December 20, 2021
Tickers
CANF
Tags
Long Ideas
Penny Stocks
Liver Cancer
From
Benzinga
Bellerophon Stock Surges After Positive Data From Sarcoidosis-Associated Pulmonary Hypertension Trial
December 17, 2021
Tickers
BLPH
Tags
Briefs
Trading Ideas
Sarcoidosis
From
Benzinga
UniQure Shares Fall After Clinical Update From Huntington's Disease Gene Therapy Trial
December 16, 2021
Tickers
QURE
Tags
Phase 1 Trial
News
General
From
Benzinga
Arcturus Shares Shoot Higher After Additional Data From COVID-19 Vaccine Programs
December 16, 2021
Tickers
ARCT
BNTX
PFE
Tags
COVID/19 Coronavirus
Small Cap
COVID/19 Vaccine
From
Benzinga
Cullinan Oncology Posts Updated Data for CLN-081 in NSCLC EGFR Exon 20 Patients
December 16, 2021
Tickers
CGEM
Tags
Biotech
Benzinga
Small Cap
From
Benzinga
Axcella Kickstarts Long COVID Phase 2 Clinical Trial
December 16, 2021
Tickers
AXLA
Tags
Phase 2 Trial
Briefs
Trading Ideas
From
Benzinga
Seres Posts Interim Microbiome Data Analysis From Failed Ulcerative Colitis Study
December 16, 2021
Tickers
MCRB
Tags
MCRB
Briefs
Trading Ideas
From
Benzinga
Vaxart to Test Cross-Reactivity of its COVID-19 Oral Vaccine Against Omicron
December 16, 2021
Tickers
VXRT
Tags
Biotech
Benzinga
COVID/19 Coronavirus
From
Benzinga
GeoVax Initiates Phase 2 Trial For COVID-19 Vaccine Booster
December 15, 2021
Tickers
GOVX
Tags
COVID/19 Vaccine
COVID/19 Coronavirus
Market News
From
Benzinga
After Roche Walks Away, Atea Puts Break On Late-Stage COVID-19 Oral Antiviral Trial
December 15, 2021
Tickers
AVIR
RHHBF
RHHBY
RHHVF
Tags
AVIR
Briefs
Phase 2 Trial
From
Benzinga
Final Data Reaffirms Efficacy Of Pfizer's COVID-19 Antiviral Treatment
December 14, 2021
Tickers
PFE
Tags
Benzinga
Biotech
Market News
From
Benzinga
Aptose Shares Fall After HM43239 Data Featured At ASH Annual Meeting, Luxeptinib, APTO-253 Update
December 14, 2021
Tickers
APTO
Tags
Penny Stocks
acute myeloid leukemia
General
From
Benzinga
Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients
December 14, 2021
Tickers
GILD
Tags
Market News
Health Care
lymphoma
From
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.